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We investigated the molecular mechanisms of cell cycle arrest and apoptotic death induced by Solanum lyratum extracts (SLE)
or diosgenin in WEHI-3 murine leukemia cells in vitro and antitumor activity in vivo. Diosgenin is one of the components
of SLE. Our study showed that SLE and diosgenin decreased the viable WEHI-3 cells and induced G0/G1 phase arrest and
apoptosis in concentration- or time-dependent manners. Both reagents increased the levels of ROS production and decreased the
mitochondrial membrane potential (ΔΨm). SLE- and diosgenin-triggered apoptosis is mediated through modulating the extrinsic
and intrinsic signaling pathways. Intriguingly, the p53 inhibitor (piﬁthrin-α), anti-Fas ligand (FasL) mAb, and speciﬁc inhibitors
of caspase-8 (z-IETD-fmk), caspase-9 (z-LEHD-fmk), and caspase-3 (z-DEVD-fmk) blocked SLE- and diosgenin-reduced cell
viability of WEHI-3 cells. The in vivo study demonstrated that SLE has marked antitumor eﬃcacy against tumors in the WEHI-3
cell allograft model. In conclusion, SLE- and diosgenin-induced G0/G1 phase arrest and triggered extrinsic and intrinsic apoptotic
pathways via p53 activation in WEHI-3 cells. SLE also exhibited antitumor activity in vivo. Our ﬁndings showed that SLE may be
potentially eﬃcacious in the treatment of leukemia in the future.
1.Introduction
In Taiwan, 4.32 per 100,000 people die each year of leukemia
according to the Department of Health, Executive Yuan, Tai-
wan in 2010s [1]. Hematopoietic stem cell transplantation,
radiotherapy, and chemotherapy agents are usually used in
the treatment for leukemia patients, but these outcomes are
not fully satisfactory [2]. The most eﬀective strategy for kill-
ing cancer cells is to induce cell cycle arrest and apoptosis
whichplaysanimportantroleasanantitumormechanismin
human leukemia cells [3]. Characteristics of apoptosis inclu-
de chromatin condensation, DNA fragmentation and mem-
brane blebbing, apoptotic bodies, translocation of phos-
phatidylserine (PS) of the plasma membrane [3–5], caspase2 Evidence-Based Complementary and Alternative Medicine
cascade of cell death signaling on extrinsic, and intrinsic-
dependent events that regulate proapoptotic and antiapop-
totic proteins [3, 6]. Arresting tumor cells to G0/G1 phase
and apoptosis may oﬀer therapeutic possibilities for treating
malignant tumors [7, 8]. It is fully reported that reagents
which promoted cell cycle arrest or apoptotic induction have
been used with medicinal plants [9, 10]. Numerous studies
had been showed that increased consumption of plant-based
diet can reduce the risk of cancer [11].
Solanum lyratum Thunberg (Solanaceae), one of the
traditional Chinese medicines (TCM) in Taiwan and China
is used to regulate immune function [12]a n dt r e a ta l l e r -
gic responses for generations [13]. Our previous study
demonstrated thatSolanum lyratum treatmentpromotedthe
activity of phagocytosis by macrophages in the peripheral
blood mononuclear cells (PBMC) and peritoneal cells from
normal and leukemia mice in vivo [14]. We also showed
that natural killer (NK) cells from the normal and leukemia
mice after SLE treatment can kill the YAC-1 target cells [14].
Therefore, the regulations of immune function might be
one of the antitumor mechanisms of SLE in leukemia cells.
However, Solanum lyratum is commonly used for treatment
of liver, lung esophagus cancer, and leukemia in the Chinese
population [15, 16]. Many studies showed that Solanum
lyratum extracts (SLE) inhibited proliferation in human
hepatoma BEL-7402 cells, gastric carcinoma SGC-7901 cells,
and melanoma A375-S2 cells in vitro and in vivo [16, 17].
SLE also triggered apoptosis in human cervical cancer HeLa
cellsthroughFas/Fasligand(FasL)expression[18]promoted
the activity of protein kinase A (PKA) in the gastric cancer
cells [19, 20] and provoked caspase-3-mediated apoptosis
in human colon cancer colo 205 cells [21]. Additionally,
SLE exhibited antitumor activity through caspase-8 and cas-
pase-9 activations and mitogen-activated protein kinase
(MAPK) regulation in Lewis lung carcinoma (LLC) cells
[22]. The goal of this study hypothesized that whether the
antileukemia activity of SLE mediates via its direct cytotoxic
eﬀect and explores the molecular mechanisms in WEHI-3
murine leukemia cells. Hence, the study focused on the cell
cycle arrest and apoptosis-induced by SLE in the WEHI-3
cells. Based on in vitro and in vivo studies, we found that
SLE inhibited cells viability induced cell apoptosis, simulta-
neously arresting the WEHI-3 cells to G0/G1 phase through
regulating activation of p53/Fas signaling and suppressed
allograft tumor in vivo.
2.MaterialsandMethods
2.1. Plant Material and Preparation of Solanum lyratum Ex-
tracts (SLE). SLE was obtained from Dr. Chao-Lin Kuo
(School of Chinese Pharmaceutical Sciences and Chinese
Medicine Resources, China Medical University) as described
previously[21].SolanumlyratumwascollectedinSeptember
2002 from Dongpu, Sinyi Township, Nantou County, Tai-
wan. The voucher specimens (CMU SL 0222) were deposited
in China Medical University. The 600g of Solanum lyratum
was extracted frequently with 50% ethanol at room tempera-
ture. The combined all ethanol extracts were ﬁltered and
evaporated under reduced pressure then get 58.44g of brow-
nish viscous residue. For this experiment, the crude extracts
were dissolved in dimethyl sulfoxide (DMSO) [21].
2.2. Chemicals and Reagents. Diosgenin, agarose, 4,6-diami-
dino-2-phenylindole dihydrochloride (DAPI), dimethyl sul-
foxide(DMSO),propidiumiodide(PI),TritonX-100,piﬁth-
rin-α (PFTα; p53 inhibitor), Tris-HCl, and ribonuclea-
seAwereobtainedfromSigma-AldrichCorp.(St.Louis,MO,
USA). 2 ,7 -dichlorodihydroﬂuorescein diacetate (H2DCF-
DA), 3,3 -Dihexyloxacarbocyanine iodide (DiOC6), RPMI-
1640 medium, L-glutamine, fetal bovine serum (FBS), Tryp-
sin-EDTA, and penicillin/streptomycin were purchased from
Invitrogen/Life Technologies(Carlsbad, CA, USA).Caspase-3,
-8, and -9 activity assay kits, caspase-3-speciﬁc inhibitor (z-
Asp-Met-Gln-Asp-ﬂuoromethyl ketone; z-DEVD-fmk), cas-
pase-8-speciﬁc inhibitor (z-Leu-Glu-His-Asp-ﬂuoromethyl
ketone; z-IETD-fmk), and caspase-9-speciﬁc inhibitor (z-
Ile-Glu-Thr-Asp-ﬂuoromethyl ketone; z-LEHD-fmk) were
bought from R&D Systems (Minneapolis, MN, USA).
Tdt-mediated deoxyuridine triphosphate nick end labeling
(TUNEL) assay kit was purchased from Roche Diagnostics
(GmBH, Mannheim, Germany). Annexin V/PI staining kit
wasboughtfromSerotec(Raleigh,NC,USA).Theseprimary
antibodies (anticaspase-3-FITC, anti-FasL, anti-p53, anticy-
clin D, anti-CDK4, anti-CDK6, anti-Fas, anti-FADD, anti-
cytochrome c, anti-Apaf-1, anti-Bcl-2, anti-Bcl-xl, anti-Bax,
anti-BAD, and anti-GAPDH), and second antibodies for
Western blotting were obtained from Santa Cruz Biotech-
nology, Inc. (Santa Cruz, CA, USA). The primary antibod-
ies (anticaspase-8, anticaspase-9, and anticaspase-3) were
obtained from Cell Signaling Technology (Danvers, MA,
USA). FITC-conjugated anti-FasL and its FITC-conjugated
isotype mAb were obtained from BD Biosciences Pharmin-
gen (San Diego, CA, USA).
2.3. Determination of Diosgenin from SLE by HPLC. Dios-
genin is isolated from SLE as described previously [15, 23].
Standard stock solution containing 5mg/mL of diosgenin
was prepared by dissolving approximately 3.1mg of com-
pound in 0.62mL methanol. HPLC analysis was performed
on SHIMADZU (Japan) two solvent delivery system model
CBM-20A together with a model RID-10A refractive index
detector. Data acquisition was performed using SHIMADZU
Class-VP software. Chromatography was carried out on a
Cosmosil 5C-18 MSII column (250×4.6mm i.d.). Isocratic
elution was performed with water and HPLC-grade metha-
nol (10/90, v/v) at a ﬂow rate of 1mL/min. The solvents were
ﬁltered through a 0.45μm of ﬁlter prior to use.
2.4. Cell Culture and SLE and Diosgenin Treatment. The mu-
rine myelomonocytic leukemia cell line (WEHI-3) was ob-
tained from the Food Industry Research and Development
Institute (Hsinchu, Taiwan). Cells were grown in 75-cm2
tissue culture ﬂasks at 37◦C under a humidiﬁed 5% CO2
atmosphere in RPMI 1640 medium containing 10% FBS,
2mM L-glutamine, 100 Units/mL penicillin, and 100μg/mL
streptomycin.Exponentiallygrowingcellsat2×105/mLwereEvidence-Based Complementary and Alternative Medicine 3
exposed to diﬀerent doses of SLE or for diﬀerent time points.
T h e0 . 1 %D M S Oi sa sav e h i c l ec o n t r o l .C e l lm o r p h o l o g i -
cal examination was determined utilizing a phase-contrast
microscope [21].
2.5. Assessment for Cell Viability. Cell viability was deter-
minedbyaPIexclusionmethodandﬂowcytometry[24,25].
WEHI-3 cells (2×105 cells/mL) in 24-well plates were incu-
batedwith0,100,200,and400μg/mLofSLEor0,25,50,and
100μM of diosgenin for 24, 48 and 72h. For incubation with
the inhibitors, cells were pretreated with 10μM of caspase-3
inhibitor,caspase-9inhibitor,andcaspase-8inhibitorfor1h,
followed by treatment with or without SLE (200μg/mL) or
diosgenin (50μM). At the indicated time courses, cells were
collectedandthenresuspendedinPBScontaining4μg/mLof
PI and then analyzed by ﬂow cytometry (FACS Calibur, Bec-
ton Dickinson, Franklin Lakes, NJ, USA) [25, 26]. All experi-
ments were performed in triplicate. Percentage of cell viabil-
itywascalculatedasaratioofSLE-ordiosgenin-treatedcells.
2.6. Analysis for Cell Cycle Progression by Flow Cytometry.
WEHI-3 cells (2×105 cells/mL) in 24-well ﬂask were expos-
ed to 200μg / m Lo fS L Eo r5 0μM of diosgenin for 0, 24, and
48h. Cells were then collected, ﬁxed in 70% ethanol over-
night, washed in PBS once, and resuspended in 500μLo f
192mM Na2HPO4, 4mM citric acid, pH 7.8 at 25◦Cf o r
30min. The cells were stained with 0.5mL of PBS containing
1mg/mLRN ase,10μg/mLPIfor30mininthedarkandthen
analyzed by ﬂow cytometry [27, 28].
2.7.AnalysisofApoptoticCellsbyDAPI/TUNELDoubleStain-
ing. TUNELstainingwasperformedaccordingtothemanu-
facturer’s protocols (in situ cell death detection kit; Roche
Diagnostics). Cells (2×105 cells/mL) in 24-well plates were
treated without or with 200μg/mL of SLE or 50μMo f
diosgenin for 48h. Cells were harvested and immediately
incubated with working strength terminal deoxynucleotidyl
transferase (Tdt) enzyme in a humidiﬁed chamber at 37◦C
for 1h. The cells were immersed in stop/wash buﬀer and
gently rinsed with PBS. FITC-labeled antidigoxigenin anti-
body was then applied to cells and incubated at 37◦Cf o r
30min in the dark. Cells were washed in PBS, stained with
DAPI, and mounted with DABCO (Sigma-Aldrich). DAPI-
andTUNEL-positivecellswerevisualizedwithaﬂuorescence
microscope [29, 30].
2.8. Assay of Early Apoptotic Cells by Annexin V/PI Double
Staining. Cells (2×105 cells/mL) in 24-well plates were in-
cubated with or without 200μg/mL of SLE or 50μM of dios-
geninfor12h,thecellswerewashedtwicewithPBSandresu-
spended in binding buﬀer (10mM HEPES/NaOH (pH 7.4),
140mM NaCl and 2.5mM CaCl2). The cells were then
stained with ﬂuorescein isothiocyanate (FITC)-Annexin V
and PI for 30min in the dark at room temperature according
to the manufacturer’s directions (Serotec Inc., Raleigh, NC,
USA). The ﬂuorescence intensity of cells was immediately
analyzed by ﬂow cytometry [21, 31, 32].
2.9. Detection of the Fas Ligand Expression by Flow Cytometry.
F a sl i g a n d( F a s L )c e l ls u r f a c ea n t i g e ne x p r e s s i o nw a sm e a -
suredbyﬂowcytometryaspreviouslydescribed[33,34].SLE
at 200μg/mL or diosgenin at 50μMt r e a t e dc e l l sw e r er i n s -
ed in PBS. FasL was analyzed by direct immunoﬂuorescence
staining. FITC-conjugated anti-FasL and its FITC-conjugat-
ed isotype mAb (BD Biosciences Pharmingen, San Diego,
CA, USA) that were from examined cells were analyzed using
aﬂ o wc y t o m e t e r[ 33, 34].
2.10.TreatmentwithAnti-FasLigand(FasL)mAborPiﬁthrin-
α (p53 Inhibitor). Cells (2×105 cells/mL) in 24-well plates
werepretreatedwith50ng/mLofanti-Fasligand(FasL)mAb
or 10μM of piﬁthrin-α (p53 inhibitor) for 1h, followed by
treatmentwithorwithout200μg/mLofSLEor50μMofdio-
sgenin for 48h. FasL blocking experiments were performed
by treatment with Fas ligand (FasL) mAb (BD Biosciences
Pharmingen, San Diego, CA, USA; 500ng/mL) or a mouse
IgG1 isotype-matched control mAb (BD Biosciences Pharm-
ingen; 500ng/mL) as previously described [33, 34].
2.11. Flow Cytometric Detections of Reactive Oxygen Species
(ROS) and Mitochondrial Membrane Potential ΔΨm.
Cells (2×105 cells/mL) in 24-well plates were exposed to
200μg / m Lo fS L Eo r5 0μM of diosgenin for 0, 6, 12, 24, and
48h. ROS and ΔΨm were assessed by cell permeable probes
H2DCF-DA (10μM) and DiOC6(500nM), respectively.
Cells were washed with PBS and resuspended in PBS
then analyzed at FL1 channel (530nm) by ﬂow cytometry
[26, 28].
2.12. Immunoﬂuorescence Staining. Cells (2×105 cells/mL)
in 4-well chamber slides were incubated with SLE
(200μg/mL) or diosgenin (50μM) for 48h. After SLE
treatment, cells were ﬁxed with iced methanol, blocked with
2% BSA, stained with anticaspase-3 monoclonal antibodies
(Santa Cruz Biotechnology, Inc.) and then FITC-conjugated
anti-mouse IgG antibody (Santa Cruz Biotechnology, Inc.).
The cells were analysed with a ﬂuorescence microscope
[35, 36].
2.13. Caspase-8 and Caspase-9 Activities Assay. Cells (total
2.5×106 cells) in 6-well plates were treated with 200μg/mL
of SLE or 50μM of diosgenin for 0, 12, 24, 36, and 48h.
Cells were harvested and lysed in a lysis buﬀer (50mM Tris-
HCl (pH 7.4), 1mM EDTA, 10mM EGTA, 10mM digitonin,
and 2mM DTT). Cell lysates (50μg protein) were incubated
with caspase-9 and -8 speciﬁc substrates (Ac-LEHD-pNA,
and Ac-IETD-pNA) (R&D Systems, Inc., Minneapolis, MN,
USA) for 1h at 37◦C. The caspase activity was determined by
measuring OD405 of the released pNA [35, 37].
2.14. Western Blotting Analysis. C e l l s( t o t a l1×107 cells) in
75-T ﬂask were incubated with or without SLE (200μg/mL)
or diosgenin (50μM) for 0, 12, 24, and 48h. Total protein
was prepared and determined as previously described [21,
27]. Protein lysates were sonicated and the supernatants
were boiled in SDS sample buﬀer for 5min. The protein4 Evidence-Based Complementary and Alternative Medicine
concentration was measured by using a BCA assay kit
(Pierce Chemical, Rockford, IL, USA). Equal amounts of cell
lysate were run on 10 to 12% SDS-polyacrylamide gel elec-
trophoresis and electrotransferred to a nitrocellulose mem-
brane by using the iBot Dry Blotting System (Invitrogen/Life
Technologies). The transferred membranes were blocked for
1h in 5% nonfat dry milk in Tris-buﬀered saline/Tween 20
and incubated with primary antibodies at 4◦C overnight.
Membranes were washed three times with Tris-buﬀered sali-
ne/Tween 20 for 10min and incubated with secondary HRP-
conjugated antibody [25, 29, 38]. The blots were developed
by using an ECL kit and Kodak Bio-MAX MR ﬁlm (Eastman
Kodak, Rochester, NY, USA).
2.15. WEHI-3 Murine Leukemia Cells Allograft Model and In
Vivo Antitumor Activity Assay. Eighteen BALB/c mice (4–6
w e e k so fa g e )w e r eo b t a i n e df r o mt h eN a t i o n a lL a b o r a t o r y
Animal Center (NLAC, Taipei, Taiwan). All mice were fed a
commercial diet and water. WEHI-3 cells (total 1×107 cells)
were resuspended in serum-free RPMI medium 1640 with
BD Matrigel basement membrane matrix (BD Biosciences)
at a 1:1 ratio (total volume 200μL). WEHI-3 cells were
subcutaneously injected into the ﬂanks of mice. Tumor mass
wasmeasuredevery4days.Whentumorsreachedanapprox-
imate volume of 100mm3, mice were selected and distri-
buted for drug studies (day 0). Animals with tumors were
randomly assigned to three treatment groups. Animals (six
mice/group) were given vehicle control (olive oil), SLE (5
and 15mg/kg) by oral gavage for QD treatment [14]. Body
weight and tumors volume were measured every 4 days with
a caliper. Tumor volumes were determined by measuring the
length(l)andthewidth(w),andthevolumeswerecalculated
as l/w2/2. The mice were sacriﬁced when the tumor burd-
enwaslessthan1800mm3 (day28)[39–42].Allexperiments
were conducted according to the Institutional Animal Care
and Use Committee (IACUC; Aﬃdavit of Approval of Ani-
mal Use Protocol, No. 98–129-N), China Medical University
(Taichung, Taiwan).
2.16. Statistical Analysis. All the statistical results were ex-
pressed as the mean ± S.E.M. of triplicate samples. Statistical
analyses of data were done using one-way ANOVA followed
by Student’s t-test, and P<0.05 were considered signiﬁcant.
3. Results
3.1. HPLC Analysis in SLE. T h ep r e v i o u ss t u d i e sh a v e
demonstratedthatdiosgeninisoneofthemajorcomponents
of the SLE [15, 23]. HPLC chromatogram of SLE analyzed
using a Cosmosil 5C-18 MSII column (250 × 4.6mm i.d.)
eluted with methanol/water (90/10, v/v) at a ﬂow rate of
1.0mL/min and with refractive index detector. The peak at
24.140min was identiﬁed as diosgenin as seen in Figure 1.
3.2. SLE and Diosgenin Inhibited Cell Proliferation, Promoted
G0/G1 Phase Arrest, and Induced Cell Death in WEHI-3 Cells.
We initially assessed the cell viability in WEHI-3 cells. In
Figure 2(a), the concentrations of 100, 200, and 400μg/mL
of SLE or 25, 50, and 100μM of diosgenin decreased the
percentageofviablecells,andtheseeﬀectsareinaconcentra-
tion-dependent manner. The half maximal (50%) inhibitory
concentration (IC50) for a 48h treatment of SLE and dio-
sgenin in WEHI-3 cell was 198.35 ± 2.64μg/mL and 50.32 ±
1.45μM, respectively. Therefore, SLE at 200μg/mL or dios-
genin at 50μM was selected for further experiments in this
study. In addition, both reagents induced the strong growth-
inhibitory and cell death eﬀects in WEHI-3 cells. The further
studies were conducted to investigate the possible mecha-
nisms addressing cell cycle arrest or cell death by inhibitory
eﬀects in SLE- and diosgenin-treated WEHI-3 cells. Our
results demonstrated that SLE and diosgenin induced G0/G1
phase arrest and cell death (sub-G1 phase) in 24 and 48h
treatments, and these eﬀects occurred in a time-dependent
manner (Figure 2(b)).
3.3. SLE and Diosgenin Induced Apoptotic Death and Caspase-
3 Activation in WEHI-3 Cells. To determine whether SLE
anddiosgenincaninducecellapoptosis,WEHI-3cellstreated
with 200μg/mL of SLE or 50μM of diosgenin in WEHI-3
cells for 12h triggered the translocation of phosphatidylser-
ine(PS)frominnersideoftheplasmamembranetotheouter
layer of the cell membrane which was examined by Annexin
V/PI analysis (Annexin positive cells: 32.89 ± 2.26% and
41.93 ± 3.50%) as shown in Figure 3(a). Figure 3(b) showed
that chromatin condensation and DNA fragmentation were
evident in WEHI-3 cells treated with 200μg/mL of SLE
or 50μM of diosgenin for 48h. To investigate if SLE- and
diosgenin-induced apoptosis is mediated through caspase-3-
dependent pathway, WEHI-3 cells were treated with or with-
out SLE (200μg/mL) or diosgenin (50μM) for 48h and then
stained with anticaspase-3 antibody. Our results shown in
Figure 3(c)indicatedthatthelevelofcaspase-3wasincreased
in nuclei in WEHI-3 cells after exposure to SLE or diosgenin.
Cells were pretreated with caspase-3 speciﬁc inhibitor (z-
DEVD-fmk) and then exposed to SLE or diosgenin. Results
showed that there is a signiﬁcant increase of cell viability in
comparison to SLE and diosgenin (Figure 3(d))t r e a t m e n t
alone sample. Our ﬁndings suggest that SLE- and diosgenin-
induced apoptosis was involved in caspase-3-dependent
pathway in WEHI-3 cells.
3.4. SLE and Diosgenin Induced Apoptosis through Extrinsic
Apoptotic Pathway in WEHI-3 Cells. It is well known that
caspase-3 can be activated in two major apoptotic pathways,
the death-receptor (extrinsic pathway), and mitochondr-
ia-mediated (intrinsic pathway) pathways [3, 6]. Our results
showed that SLE- and diosgenin-induced apoptosis might
be through caspase-3-dependent signaling (Figures 3(c) and
3(d)). Thus, we determined whether the death receptor (ex-
trinsic pathways) contributes to SLE- and diosgenin-induced
apoptosis. Figure 4(a) indicates that SLE (200μg/mL) and
diosgenin (50μM) treatments time dependently caused cas-
pase-8 activity. Cells were pretreated with caspase-8-speciﬁc
inhibitor (z-IETD-fmk) and then exposed to SLE or dios-
genin, the result showed that there is a signiﬁcant decrease
in caspase-8 activity (Figure 4(a)) and an increase in cell
viability (Figure 4(b)) in comparison to SLE or diosgeninEvidence-Based Complementary and Alternative Medicine 5
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Figure 1:ThecontentofdiosgenininSLEwasanalyzedbyHPLC.HPLCwasperformedonSHIMADZU(Japan)twosolventdeliverysystem
model CBM-20A together with a model RID-10A refractive index detector. Data acquisition was performed using SHIMADZU Class-VP
software. Chromatography was carried out on a Cosmosil 5C-18 MSII column (250 × 4.6mm i.d.). Isocratic elution was performed with
water and HPLC-grade methanol (10/90, v/v) at a ﬂow rate of 1mL/min. Pure diosgenin (peak 1 and peak 2) showed a retention time at
23.995min (top), SLE (peak 3 and peak 4) showed a retention time at 24.140min. (middle) and overlapping analysis (bottom).
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Figure 3: SLE- and diosgenin-induced apoptosis and caspase-3 activation in WEHI-3 cells. Cells were treated with 200μg/mL of SLE or
50μM of diosgenin for 12h. (a) Annexin V/PI analysis was determined by ﬂow cytometric assay. Apoptotic cell population (Annexin
V positive cells) was quantiﬁed as described in materials and methods. Data are presented as the mean±S.E.M. of three independent
experiments.∗, P<0.05, signiﬁcantly diﬀerent compared with control treatment. Cells were treated with 200μg/mL of SLE or 50μMo f
diosgenin for 48h. (b) DAPI/TUNEL analysis and (c) caspase-3 protein location were determined by immunostaining and photographed
by ﬂuorescence microscopic systems as described in materials and methods (400X) (↑DNA fragmentation). (d) Cells were pretreated with
speciﬁc inhibitor of caspases-3 (z-DEVD-fmk) for 1h after exposure to SLE (200μg/mL) or diosgenin (50μM) for 48h exposure. The cells
were collected to determine the percentage of viable cells. Data are presented as the mean±S.E.M. of three independent experiments. ∗,
P<0.05, signiﬁcantly diﬀerent compared with SLE-treated cells.
treatments alone sample. Figure 4(c) revealed that FasL
protein level was increased in SLE- and diosgenin-treated
WEHI-3 cells by ﬂow cytometry. It is reported that p53-
inducible proapoptotic genes triggered apoptosis through
death-receptor apoptotic pathway [43, 44]. Cells were pre-
treated with p53 inhibitor (piﬁthrin-α;P F T α) or anti-FasL
mAb and then exposed to SLE or diosgenin. Figure 4(d)
showed that there is a signiﬁcant increase in cell viability
whenincomparisontoSLE-ordiosgenin-treatedalonesam-
ples. Our results suggest that SLE- and diosgenin-induced
apoptosis might fully carried out through p53-mediated
extrinsic apoptotic pathways in WEHI-3 cells.
3.5. SLE and Diosgenin Triggered Apoptosis through Intrinsic
PathwayinWEHI-3Cells. Wedeterminedthemitochondrial
apoptotic signals if contribute to SLE- or diosgenin-induced
apoptosis. In Figure 5(a), the results showed that SLE
(200μg/mL) or diosgenin (50μM) stimulated caspase-9 acti-
vity in a time-dependent eﬀect in WEHI-3 cells. Cells were
pretreated with caspase-9-speciﬁc inhibitor (z-LEHD-fmk)
and then exposed to SLE or diosgenin, the result showed
that there is a signiﬁcant decrease in caspase-9 activity
(Figure 5(a)) and an increase in cell viability (Figure 5(b))
in comparison to SLE or diosgenin treatments alone cells.
We examined the eﬀects of SLE and diosgenin on the ROS
production and ΔΨm. Both reagents promoted ROS pro-
duction (Figure 5(c)) and loss of ΔΨm (Figure 5(d))a f t e r
12h treatment in WEHI-3 cells. Cells were pretreated with
N-acetylcysteine (NAC, ROS scavenger) and treated with
SLE. We found that the increased the percentage of viable
WEHI-3 cells occurred when compared SLE and diosgenin-
treated cells (data not shown). Our ﬁndings proposed thatEvidence-Based Complementary and Alternative Medicine 7
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Figure 4: Eﬀects of SLE and diosgenin on WEHI-3 cells in the extrinsic apoptotic pathway. Cells were pretreated with speciﬁc inhibitors of
caspases-8 (z-IETD-fmk) for 1h after exposure to SLE (200μg/mL) or diosgenin (50μM) for 12, 24, 36, and 48h. (a) The whole-cell lysates
were subjected to caspase-8 activity and (b) cells were collected after SLE or diosgenin for a 48h treatment to determine the percentage of
viable cells. (c) Cells were incubated with 200μg/mL of SLE or 50μM of diosgenin for 24h, and FasL protein expression was detected by
immunostaining and analysis by ﬂow cytometry. (d) Cells were pretreated with anti-FasL mAb or speciﬁc inhibitor of p53 (PFTα)f o r1h
after exposure to SLE (200μg/mL) or diosgenin (50μM) for a 48h exposure. Cells were collected to determine the percentage of viable cells.
Data are presented as the mean±S.E.M. of three independent experiments. ∗, P<0.05, signiﬁcantly diﬀerent compared with SLE-treated
cells.
SLE- and diosgenin-induced apoptosis was through ROS
production and intrinsic pathways in WEHI-3 cells.
3.6. Eﬀects of SLE and Diosgenin on G0/G1 Phase and
Apoptosis-Associated Protein Levels in WEHI-3 Cells. We in-
vestigatedtheproteinlevelsoftheG0/G1 phaseandapoptosis
by Western blotting. As shown in Figure 6(a), SLE and dios-
genin caused an increase in the protein level of p53 and
decreased the protein levels of CDK4, CDK6, and cyclin
D in WEHI-3 cells. Results shown in Figure 6(b) indicated
that SLE and diosgenin increased the death receptor path-
way-associated protein levels, including Fas/CD95, FasL,
FADD, and cleavage-caspase-8. Furthermore, mitochondrial
pathway-related protein levels (cytochrome c,A p a f - 1 ,B a x ,
Bad,andcleavage-caspase-9)wereincreased,butthelevelsof
Bcl-2andBcl-xlweredecreasedinSLEanddiosgenin-treated
WEHI-3 cells (Figure 6(c)).8 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Eﬀects of SLE and diosgenin on WEHI-3 cells in the intrinsic apoptotic pathway. Cells were pretreated with speciﬁc inhibitor
of caspases-9 (z-LEHD-fmk) for 1h after exposure to SLE (200μg/mL) or diosgenin (50μM) for 12, 24, 36, and 48h. (a) The whole-cell
lysates were subjected to caspase-9 activity assay and (b) cells were collected after SLE or diosgenin for a 48h treatment to determine the
percentage of viable cells. Data are presented as the mean±S.E.M. of three independent experiments. ∗, P<0.05, signiﬁcantly diﬀerent
compared with SLE treatment. (c) The reactive oxygen species (ROS) of SLE- or diosgenin-treated WEHI-3 cells from each time point
were measured by staining with H2DCF-DA. (d) The mitochondrial membrane potential (ΔΨm) of both reagents-treated WEHI-3 cells was
measured by staining with DiOC6. Data are presented as the mean±S.E.M. of three independent experiments. ∗, P<0.05, signiﬁcantly
diﬀerent compared with 0h treatment.
3.7. Antitumor Activity of SLE in WEHI-3 Cells Allograft
Model. Basedonourinvitrostudies,weexaminedtheinvivo
antitumor activities of SLE in a BALB/c mouse WEHI-3 allo-
graft model [42]. Representative tumor weights from the
WEHI-3 allograft mice treated with or without SLE were
shown in Figure 7(a) and 7(b). SLE (15mg/kg; QD; oral)
signiﬁcantly decreased the tumor weight by 56.84% compar-
ed with control mice. As seen in Figure 7(c),S L E( 5a n d
15mg/kg; QD; oral) reduced tumor volume compared with
control after treatment from day 12 to 28. Figure 7(d)
shows that the body weights of the allograft mice were
not signiﬁcantly diﬀerent after treatment with SLE (5 and
15mg/kg; QD; oral) from day 0 to 28. SLE signiﬁcantly pre-
vented the loss of body weight compared with the control
group. Our results proposed that SLE reduced the tumor size
and processed antitumor activity in the WEHI-3 allograft
model.
4. Discussion
Traditional Chinese medicines (TCM) were appiled to
prevent or therapy various tumor are marked with their highEvidence-Based Complementary and Alternative Medicine 9
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Figure 6: SLE and diosgenin altered the levels of G0/G1 p h a s ea n da p o p t o t i cr e l a t i v ep r o t e i n si nW E H I - 3c e l l s .C e l l sw e r ee x p o s e dt oS L E
(200μg/mL) or diosgenin (50μM) and then incubated for 12, 24, and 48h. The protein levels of (b) p53, cyclin D, CDK4, and CDK6,
(b) Fas/CD95, FasL, FADD, Caspase-8, and GAPDH (b), and (c) cytochrome c, Apaf-1, Bcl-2, Bcl-xl, Bax, Bad, caspase-9, caspase-3, and
GAPDH in SLE-treated WEHI-3 cells were determined by Western blotting. Data are presented as the mean±S.E.M. of three independent
experiments. ∗, P<0.05, signiﬁcantly diﬀerent compared with 0h treatment.
antitumor activity but low toxicity in normal cells [9, 10].
SLEisanactiveTCMwithvariousimmuneandpharmacolo-
gical eﬀects on antitumor activity [14–16]. Our earlier study
has veriﬁed that SLE aﬀected immune response in vivo [14].
Herein, we further evaluated the antileukemia eﬀects of SLE
and diosgenin on WEHI-3 cells in vitro. Our results demon-
strated that SLE signiﬁcantly inhibited the viability in
WEHI-3 cells (Figure 2(a)). Importantly, SLE had a relative
low toxicity eﬀect in normal PBMC cells, which suggested
that SLE might be an eﬀective and safe antitumor reagent
[14]. In our study, the inhibition of tumor growth eﬀect of
SLE on the WEHI-3 cell allograft model in the SLE-treated
mice was observed (Figure 7). Due to these observations,
SLE is safety as a leukemia therapeutic reagent. In addition,
our novel ﬁndings showed that SLE exhibited two important
mechanisms in antileukemia eﬀects; one is immune regu-
lation [14] and the other is direct cytotoxicity eﬀects and
cell growth through induction of G0/G1 phase arrest and
apoptosis in WEHI-3 cells.
It has been reported that several mechanisms for SLE-
mediated inhibition of tumor cell survival and induction of
apoptosis occurred in human cancer cells [16–21]. In our
previous study, production of ROS in colo 205 colon can-
cer cells after SLE treatment might be involved in a direct
anticancer eﬀect, inhibition of cell proliferation and induc-
tion of apoptosis [21]. Herein, we characterized the eﬀects of
SLE on WEHI-3 cells. Modulation of expression and func-
tionofcellcycleregulatoryproteinssuchascyclin-dependent
kinase inhibitor (CKI), cyclins, and CDK provides a crucial
mechanism for the control of cell growth [45, 46]. In regula-
tion of transition from G1 to S, activation of CDK4, CDK6,
and cyclin D is one of the important mechanisms [47]. SLE
induced G0/G1 phase arrest (Figure 2(b)) and inhibited the
cyclin D, CDK4, and CDK6 protein levels, but it exhibited10 Evidence-Based Complementary and Alternative Medicine
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Figure 7: SLE inhibited tumor growth in the WEHI-3 cells allograft model. Eighteen BALB/c mice were subcutaneously implanted with
1×107 WEHI-3 cells. When tumors reached the volume of 100mm3, the mice were randomly divided into three groups (six mice/group).
Group 1 was orally treated with control vehicle (olive oil) daily; group 2 was orally treated with 5mg/kg of SLE daily; group 3 was orally
treated with 15mg/kg of SLE daily. At day 28, all animals were sacriﬁced. Representative (a) animals with tumor, (b) tumor weight, (c) solid
tumor volume, and (d) body weight from each animal were shown. Data are presented as the mean±S.E.M. of six animals at day 0 to 28
after tumor implantation. ∗, P<0.05, signiﬁcantly diﬀerent compared with control.
p53 protein level which was associated with cell cycle arrest
(Figure 6(a))i nW E H I - 3c e l l s .T h ef u n c t i o no fp 5 3p l a y s
an important role in inducing cell cycle checkpoints and
apoptosisinhumanandmurinecellsfollowingROS-induced
DNA damage [48]. Our results demonstrated that induction
of p53 by SLE not only caused G0/G1 phase arrest but also
triggered apoptosis in WEHI-3 cells. Pretreatment with
PFTα in SLE-treated WEHI-3 cells restored the cell viability
(Figure 4(d)), suggesting the functional involvement in
p53-dependent pathway. To conﬁrm this hypothesis, further
investigations such as those using p53-speciﬁc siRNA are
needed.
Apoptosis is important in normal cell homeostasis and
apoptosis induction is one of the best strategies for cancer
treatment [4, 49]. Apoptotic signaling pathway can be divid-
ed into: (i) the death receptor includes Fas/FasL, tumor necr-
osis factor (TNF)/TNF receptors, and death receptor 4, 5
(DR4, 5)/DR4, 5 receptors and their downstream molecules
are caspases-8 [4, 6]; (ii) the mitochondria-mediated path-
way shows apoptotic stimuli induced by radiation, ROS pro-
duction, and chemotherapy. Loss of ΔΨm could cause cyto-
chrome c, Apaf-1, procaspase-9 releases and lead to the acti-
vation of the caspase cascade [4]. However, the cross-talk
between these two apoptotic pathways also exists [11, 37, 50,
51]. In this study, we observed that SLE induced cell death
withcharacteristicsof apoptosis (Figure 3).Our data showed
that the activities and protein levels of caspase-8, -9, and
-3 were increased in SLE-treated WEHI-3 cells in a time-
dependent manner (Figures 3–5). The extrinsic and intri-
nsic apoptotic pathways-associated proteins (Figure 6)w e r e
changed, which subsequently promoted caspase-8 and cas-
pase-9 activation to activate downstream eﬀectors caspase-
3 in SLE-treated WEHI-3 cells. Lee et al. reported that
hexane fraction of Solanum lyratum herba induced apoptosis
through activated caspase-8, -9, and -3 proteins in LLC
cells [22]. The previous studies [18–20, 22]s u p p o r t e do u rEvidence-Based Complementary and Alternative Medicine 11
suggestions to show that SLE induced apoptosis in WEHI-3
cells through both extrinsic- and intrinsic-dependent signal-
ing pathways.
Thepresentstudyalsoinvestigateddiosgenin,afoodsap-
onin and one of the compounds isolated from SLE [15, 23,
52], whether aﬀects murine leukemia WEHI-3 cells. Impor-
tantly, we also found that there are many similar results in
diosgenin-treated WEHI-3 cells when compared with that in
WEHI-3 cells after SLE exposure. Based on these ﬁndings,
diosgenin-provoked apoptosis in WEHI-3 cells is involved
in the p53-regulated both extrinsic and intrinsic signaling
pathways. This report is agreed with other studies describ-
ed by Bertrand et al. regarding diosgenin treatment that trig-
gered subsequent extrinsic and intrinsic apoptotic signaling
in human erythroleukemia (HEL) cells [52, 53]. Moreover,
our data shown in Figure 2(b) is consistent with the previous
research that diosgenin promoted G1/G0 phase arrest in pri-
mary human thyrocytes [49, 54]. Intriguingly, Srinivasan
et al. stated that diosgenin processed chemotherapeutic
eﬀects through targeting Akt-mediated NF-κBa n dM A P K
(prosurvival) signaling in human breast carcinoma (BCa)
cells [49]. Hence, we suggest that SLE and diosgenin might
be as potent anticancer agents for treating leukemia patients.
In summary, we demonstrated the molecular mecha-
nisms underlying SLE-induced antitumor activity in WEHI-
3 murine leukemia cells in vitro and in vivo. SLE inhibited
cell proliferation in WEHI-3 murine leukemia cells through
G0/G1 phasearrest, extrinsic- and intrinsic-related pathways,
which is involved in p53 activation. Understanding the
manner of SLE-aﬀected cell cycle progression and triggered
apoptotic pathways will facilitate the development of treat-
ment of leukemia in the future.
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